Akihiro Yamamoto

Akihiro Yamamoto

Auto-generated profile, based on publicly available information

Akihiro Yamamoto

The University of Osaka Graduate School of Medicine

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
NMNobuhiko Mori
Nobuhiko Mori
YHYuhei Hoshikuma
Yuhei Hoshikuma
KHKoichi Hosomi
Koichi Hosomi
AYAkihiro Yamamoto
Akihiro Yamamoto
TSTakeshi Shimizu
Takeshi Shimizu
HKHaruhiko Kishima
Haruhiko Kishima
Background: Neuropathic pain (NP) remains difficult to manage because conventional pharmacological therapies often have limited efficacy and intolerable side effects. Noninvasive neuromodulation techniques have emerged as potential alternatives with fewer adverse effects. Meta-analyses of randomized controlled trials suggest that high-frequency repetitive transcranial magnetic stimulation over the primary motor cortex has analgesic effects; however, its efficacy is modest and restricted by the inability to stimulate deeper brain regions. Low-intensity transcranial focused ultrasound stimulation (TUS) is a novel approach that enables precise targeting of deep brain structures and modulation of neural activity. Although promising in preclinical and preliminary human studies, its long-term therapeutic efficacy for NP remains unknown. Objective: This trial aims to explore the therapeutic effects and safety of repeated TUS sessions in patients with NP. Methods: This randomized, participant-blinded, placebo-controlled, 3-arm, parallel-group clinical trial will enroll 39 participants with NP (pain duration ≥3 months; pain intensity ≥4 on the numerical rating scale). Participants will be randomly allocated to one of three groups: (1) TUS targeting the primary motor cortex, (2) TUS targeting the posterior superior insula, or (3) sham stimulation. Each participant will undergo weekly sessions for 8 weeks. The primary outcome is change in weekly average pain intensity scores recorded in a pain diary. Secondary outcomes include additional pain scales, quality of life measures, psychological assessments, quantitative sensory testing, motor cortical excitability, and adverse events. Results: The first participant was enrolled on April 30, 2025, and 20 participants had been enrolled as of February 28, 2026, with enrollment ongoing. The final analysis will be conducted after completion of follow-up and data verification. Conclusions: To our knowledge, this will be the first randomized controlled trial to examine the long-term therapeutic effects of repeated low-intensity TUS for NP. It will provide exploratory proof-of-concept data regarding its clinical efficacy and safety.

7 October 2025 in Neuropsychopharmacology Reports
Verified
Journal Article
Open access
KYKeiko Yamada
Keiko Yamada
AYAkihiro Yamamoto
Akihiro Yamamoto
UKUeno Keita
Ueno Keita
YTYukari Takahashi
Yukari Takahashi
MUMasaya Ueda
Masaya Ueda
FKFusao Kato
Fusao Kato
Background: Patients' “pain attributions,” or their beliefs about chronic pain causes, critically affect pain experience and recovery, potentially modulating responses to analgesics and psychotropics. Since many pain‐mitigating drugs also impact psychological processes and brain functions underlying these attributions, such processes are relevant targets. The Chronic Pain Attribution Scale (CPAS) by Ashar et al. (2023) quantifies these beliefs. A Japanese version (CPAS‐J) is needed to assess this psychologically relevant construct in Japanese populations. This study aimed to develop and linguistically validate the CPAS‐J. Methods: The CPAS‐J was developed following International Society for Pharmacoeconomics and Outcomes Research guidelines, with permission from the original author. The process included forward translation by eight bilingual medical experts, reconciliation by a pain research team, back‐translation by an independent translator, review by the original author, and a final consensus discussion to establish the definitive CPAS‐J. Results: The linguistic validation identified challenges in distinguishing “cause” from “trigger” in Japanese. To enhance comprehensibility, the team combined “kikkake” (initiating factor) and “gen'in” (broader cause/origin). The finalized CPAS‐J assesses perceived causes of pain. Conclusions: The CPAS‐J was successfully developed through a rigorous process. This tool supports research on pain attributions in Japanese‐speaking populations and may improve our understanding of treatment responses by assessing a key psychological dimension of chronic pain that is linked to brain‐based processes.

10 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
NMNobuhiko Mori
Nobuhiko Mori
YHYuhei Hoshikuma
Yuhei Hoshikuma
KHKoichi Hosomi
Koichi Hosomi
AYAkihiro Yamamoto
Akihiro Yamamoto
TSTakeshi Shimizu
Takeshi Shimizu
HKHaruhiko Kishima
Haruhiko Kishima
Introduction: Neuropathic pain (NP) remains difficult to manage because conventional pharmacological therapies often have limited efficacy and intolerable side effects. Non-invasive neuromodulation techniques have emerged as potential alternatives with fewer adverse effects. Meta-analyses of randomised controlled trials suggest that high-frequency repetitive transcranial magnetic stimulation over the primary motor cortex has analgesic effects; however, its efficacy is modest and restricted by the inability to stimulate deeper brain regions. Low-intensity transcranial focused ultrasound stimulation (TUS) is a novel approach that enables precise targeting of deep brain structures and modulation of neural activity. Although promising in preclinical and preliminary human studies, its long-term therapeutic efficacy for NP remains unknown. This trial aims to evaluate the therapeutic effects and safety of repeated TUS sessions in patients with NP. Methods and analysis: This randomised, participant-blinded, placebo-controlled, three-arm, parallel-group clinical trial will enrol 39 participants with NP (pain duration ≥ 3 months; pain intensity ≥ 4 on the Numerical Rating Scale). Participants will be randomly allocated to one of three groups: (1) TUS targeting the primary motor cortex, (2) TUS targeting the posterior superior insula, or (3) sham stimulation. Each participant will undergo weekly sessions for eight weeks. The primary outcome is change in weekly average pain intensity scores recorded in a pain diary. Secondary outcomes include additional pain scales, quality of life measures, psychological assessments, quantitative sensory testing, motor cortical excitability, and adverse events. Ethics and dissemination: The protocol has been approved by the University of Osaka Clinical Research Review Board. Written informed consent will be obtained from all participants. Findings will be disseminated via scientific presentations and peer-reviewed publications. Trial registration number: jRCTs052240227 STRENGTHS AND LIMITATIONS OF THIS STUDY: ⇒ This is the first randomised, participant-blinded, placebo-controlled clinical trial evaluating the long-term effects of transcranial focused ultrasound stimulation (TUS) for neuropathic pain. ⇒ TUS is a novel, non-invasive technique that can precisely target deep brain areas using a navigation system, offering the potential to modulate brain function. ⇒ The single-blind design (participants only) may introduce a risk of performance bias, as operators cannot be blinded owing to technical constraints. ⇒ The small sample size may limit statistical power to detect subtle between-group differences.